Estrategias contemporáneas para el tratamiento de la hipertensión arterial pulmonar en Argentina. Recomendaciones conjuntas de la Federación Argentina de Cardiología, Sociedad Argentina de Cardiología y Asociación Argentina de Medicina Respiratoria
DOI:
https://doi.org/10.63600/54wc1789Palabras clave:
Hipertensión arterial pulmonar, Tratamiento, AlgoritmoResumen
La hipertensión arterial pulmonar es una enfermedad progresiva y grave caracterizada por remodelado vascular pulmonar y subsecuente falla del ventrículo derecho. En Argentina, el abordaje de esta patología enfrenta serios desafíos sanitarios, evidenciados por demoras diagnósticas, subutilización de terapias recomendadas y dificultades tanto para el acceso y mantenimiento a largo plazo del tratamiento. El paradigma médico actual promueve un manejo dinámico y multiparamétrico centrado en la estratificación de riesgo para alcanzar el bajo riesgo a largo plazo. El tratamiento farmacológico se basa tradicionalmente en tres vías clásicas (óxido nítrico, endotelina y prostaciclinas), complementándose recientemente con fármacos innovadores modificadores de la enfermedad como sotatercept. Sin embargo, la complejidad del manejo, los elevados costos de los fármacos específicos y las dificultades en la provisión periódica de la medicación generan problemas de adherencia y equidad en el acceso, haciendo urgente el desarrollo de políticas públicas de salud adaptadas a la realidad local.
Referencias
1. Humbert M, Kovacs G, Hoeper MM, et al. ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43:3618-3731
2. Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024 64:2401325
3. Guan A, Dai Z, Lin J, et al. Global disease burden of pulmonary arterial hypertension: patterns and inequality in 1990-2021, with projections to 2035. BMC Public Health. 2026; 26:4
4. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991, 115:343-9
5. Iwahori T, Hayashi Y, Tsuchiya H, et al. Regional Disparities in Access to Specialized Facilities and Prescription Preference for Initial Pulmonary Arterial Hypertension Treatment - A Nationwide Study Using the National Database of Health Insurance Claims. Circ J 2026. Epub ahead of print. PMID: 41605661.
6. Chang KY, Duval S, Badesch DB, et al. Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. J Am Heart Assoc 2022; 11:e024969
7. Xie W, Yu Y, Huang Q, et al. Epidemiology and management patterns of chronic thromboembolic pulmonary hypertension in China. Chin Med J (Engl) 2025; 138:1000-1002
8. Mendes AA, Roncal CGP, Oliveira FRA, et al. Demographic and clinical characteristics of pulmonary arterial hypertension caused by schistosomiasis are indistinguishable from other etiologies. Rev Soc Bras Med Trop 2020; 53:e20190418.
9. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006, 173(9):1023-30.
10. Benza RL, Gomberg-Maitland M, Elliott CG, et al. The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. Chest. 2019; 156:323-337.
11. Hoeper MM, Simon R Gibbs J. The changing landscape of pulmonary arterial hypertension and implications for patient care. Eur Respir Rev. 2014; 23:450-7
12. Yogeswaran A, Annis JS, Fünderich M, et al. Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment. EBioMedicine. 2026; 123:106063
13. Toro V, Mougin M, Brossat C, et al. Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension. Circulation. 2026; 153:516-533
14. Talavera ML, Cáneva JO, Favaloro LE et al. Hipertensión arterial pulmonar Registro de un centro de referencia en Argentina. RAMR 2014; 2: 144-152
15. Echazarreta DF, Perna ER, Coronel ML, et al. Collaborative registry of pulmonary hypertension in Argentina (RECOPILAR). Final analysis. Medicina (B Aires); 2021;81:180-190.
16. Silva Croome N, Costas martignano P, Lema L et al. Argen HP: Registro Intersocietario de Hipertensión Pulmonar en Argentina. Análisis del registro multicéntrico ARGEN-HP. Trabajo N° 0735, presentado en el 51° Congreso Argentino de Cardiología de la Sociedada Argentina de Cardiología 2025: p. 246. Abstract.
17. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J 2016; 37:67-119
18. Del Pozo R, Cruz-Utrilla A, Escribano-Subias P. Prognostic Stratification and Treatment for Pulmonary Arterial Hypertension. Gaps and Promising Remedies. Arch Bronconeumol 2023; 59:617-618
19. van de Veerdonk MC, Marcus JT, Westerhof N, et al. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. Chest. 2015;147:1063-1071
20. Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J 2018; 39:4175-4181
21. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017; 50:1700740
22. Hjalmarsson C, Kjellström B, Jansson K, et al. Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment. ERJ Open Res 2021; 7:00854-2020
23. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017; 50:1700889
24. Kylhammar D, Hjalmarsson C, Hesselstrand R, et al. Predicting mortality during long-term follow-up in pulmonary arterial hypertension. ERJ Open Res 2021; 7:00837-2020
25. Yogeswaran A, Richter MJ, Sommer N, et al. Advanced risk stratification of intermediate risk group in pulmonary arterial hypertension. Pulm Circ 2020; 10:2045894020961739
26. Hoeper MM, Pausch C, Olsson KM, et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J 2022; 60:2102311
27. Boucly A, Weatherald J, Savale L, et al. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. Eur Respir J. 2022 Jun 30;59(6):2102419.
28. Ahmed A, Ahmed S, Kempe D et al. Evaluation of the European Society of Cardiology/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator. Eur Heart J Open. 2023 3:oead012.
29. Benza RL, Kanwar MK, Raina A, et al. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension. Chest 2021;159: 337–346.
30. D'Alto M, Badagliacca R, Argiento P, et al. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension. Chest. 2020;157:376-383.
31. Badagliacca R, Papa S, Matsubara H, et al The importance of right ventricular evaluation in risk assessment and therapeutic strategies: Raising the bar in pulmonary arterial hypertension. Int J Cardiol. 2020 Feb 15;301:183-189
32. Diez M, Cáneva J, Diez A, Perna ER, et al. START Investigators. Risk stratification, prognosis, and survival in a pulmonary arterial hypertension cohort in Latin America. A multicenter study. Respir Med Res. 2023; 83:100945.
33. Conde RE, Diez M, Dueñas R, et al. Manejo clínico de la hipertensión arterial pulmonar. Relevancia del ventrículo derecho. Medicina (B Aires). 2021;81:624-636.
34. Badagliacca R, Poscia R, Pezzuto B, et al. Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension. J Heart Lung Transplant. 2017; 17:32041-7.
35. Badagliacca R, Raina A, Ghio S, et al. Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension. J Heart Lung Transplant. 2018;37:365-375
36. Tello K, Axmann J, Ghofrani HA, et al. Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension. Int J Cardiol 2018; 266: 229–235
37. Vicenzi M, Caravita S, Rota I, et al. The added value of right ventricular function normalized for afterload to improve risk stratification of patients with pulmonary arterial hypertension. PLoS One 2022; 17: e0265059
38. El-Kersh K, Zhao C, Elliott G, et al. Derivation of a risk score (REVEAL-ECHO) based on echocardiographic parameters of patients with pulmonary arterial hypertension. Chest 2023;163:1232-44.
39. Ghio S, Badagliacca R, D'Alto M, et al. Right ventricular phenotyping in incident patients with idiopathic pulmonary arterial hypertension. J Heart Lung Transplant. 2024; 43:1668-1676
40. Badagliacca R, Ghio S, D’Alto M, et al. Relevance of echocardiography-derived phenotyping in pulmonary arterial hypertension patients treated with initial oral combination therapy. Am J Respir Crit Care Med 2024; 210:362-365
41. Lescano A, Conde R, Caneva J, et al. Mapping right ventricular adaptation in pulmonary arterial hypertension: insights from a six-phenotype model. Eur Heart J 2025; 46: ehaf784.2934
42. Dardi F, Boucly A, Benza R, et al Risk stratification and treatment goals in pulmonary arterial hypertension. Eur Respir J. 2024;64:2401323
43. Sahay S, Visovatti S, Tonelli AR, et al. International Society for Heart and Lung Transplantation (ISHLT) Consensus Statement on Risk Stratification in Pulmonary Arterial Hypertension. J Heart Lung Transplant. 2025;44:e73-e131
44. Badagliacca R, Vizza CD, Lang I, et al. Pulmonary pressure recovery in idiopathic, hereditary and drug and toxin-induced pulmonary arterial hypertension: determinants and clinical impact. Vasc Pharm 2022;146:107099.
45. Boucly A, Beurnier A, Turquier S, et al. Risk stratification refinements with inclusion of haemodynamic variables at follow-up in patients with pulmonary arterial hypertension. Eur Respir J. 2024; 64:2400197.
46. Coronel ML, Diez M, Lema L. Recomendaciones para la realización de cateterismo cardíaco derecho en hipertensión pulmonar. Documento conjunto de la Federación Argentina de Cardiología y Sociedad Argentina de Cardiología. Rev Fed Arg Cardiol. 2022; 51 (Suplemento 2): 4-22
47. Weatherald J, Boucly A, Chemla D, et al. Prognostic value of follow-up hemodynamic variables after initial management in pulmonary arterial hypertension. Circulation 2018;137:693-704.
48. Ghio S, D’Alto M, Badagliacca R, et al. Prognostic relevance of pulmonary arterial compliance after therapy initiation or escalation in patients with pulmonary arterial hypertension. Int J Cardiol 2017;230:53-8.
49. Guignabert C,Aman J,Bonnet S, etal. Pathology and pathobiology of pulmonary hypertension: current insights and future directions. Eur Respir J. 2024; 64: 2401095
50. Weiss A, Boehm M, Egemnazarov B, et al. Kinases as poten tial targets for treatment of pulmonary hypertension and right ventricular dysfunction. Br J Pharmacol 2020; 1–23
51. Frantz RP, McLaughlin VV, Sahay S, et al. Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double blind, placebo controlled phase 2 trial. Lancet Respir Med. 2024;12(7):523–34
52. Guignabert C, Humbert M. Targeting transforming growth factor-β receptors in pulmonary hypertension. Eur Respir J 2021; 57: 2002341.
53. Guignabert C, Savale L, Boucly A, Thuillet R, Tu L, Ottaviani M, et al. Serum and pulmonary expression profiles of the activin signaling system in pulmonary arterial hypertension. Circulation 2023; 147:1809–1822.
54. Boucly A, Song S, Keles M, et al. Clustering Patients with pulmonary hypertension using the plasma proteome. American Journal of Respiratory and Critical Care Medicine 2025; 211 (8): 1492-1503
55. Gerhardt F, Fiessler E, Olsson KM, et al. Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era. Circulation 2024;149:1549-64
56. Rich S, Kaufmann E, Levy PS. The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension. N Engl J Med. 1992;327:76-81.
57. Sitbon O, Humbert M, Jaïs X, et al. Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension. Circulation. 2005;111:3105-11.
58. Cascino TM, McLaughlin VV. Upfront Combination Therapy for Pulmonary Arterial Hypertension: Time to Be More Ambitious than AMBITION. Am J Respir Crit Care Med. 2021;204:756-9.
59. Boucly A, Savale L, Jaïs X, et al. Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2021;204:842-54
60. Galiè N, Barberà JA, Frost AE, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015;373:834-44
61. Habib NG, Adhia A, Lopez D, et al. Selection of Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension: A Comprehensive Narrative Review. Adv Ther. 2026;43:468-519
62. Grünig E, Jansa P, Fan F, et al. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. J Am Coll Cardiol 2024; 83:473-484
63. Barnes H, Brown Z, Burns A, Williams T. Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database Syst Rev. 2019(1):CD012621
64. Garcia AR, Blanco I, Ramon L, et al. Predictors of the response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension: an analysis of the Spanish registry. Respir Res. 2023; 24:223
65. Hoeper MM, Al-Hiti H, Benza RL, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2021;9:573-84
66. Hoeper MM, Simonneau G, Corris PA, et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J. 2017;50:1602425.
67. Rahaghi FF, Trivieri MG, Sahay S. The role of riociguat in combination therapies for pulmonary arterial hypertension. Respir Med. 2023; 211:107196
68. Mihalek AD, Scott CD, Mazimba S. Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective. Vasc Health Risk Manag. 2022;18:823-32
69. Galiè N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353: 2148–2157
70. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119: 2894–2903
71. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117:3010–3019.
72. Ghofrani HD, Galiè N, Grimminger F, et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369:330-340
73. Barst RJ, Rubin LJ, Long WA, et al. A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension. N Engl J Med. 1996;334(5):296-301.
74. Simonneau G, Barst RJ, Galie N, et al. Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2002;165(6):800-4.
75. Lescano A, Giacommi G, Botta CE, et al. Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in Argentina. Ther Adv Respir Dis; 2022; 16:17534666221132735.
76. Sitbon O, Channick R, Chin KM, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015;373:2522-33.
77. Chin KM, Sitbon O, Doelberg M, et al. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. J Am Coll Cardiol 2021; 78:1393-1403.
78. Coghlan JG, Gaine S, Channick R, et al. Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension. ERJ Open Res. 2023;9:00456-2022.
79. Saleh KM, Mallat J, Mohammed S, et al. Comparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis. Front Med (Lausanne). 2025;12:1643220.
80. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425–1436
81. Lau EMT, Giannoulatou E, Celermajer DS, et al. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol 2017; 14: 603–614
82. Sitbon O, Boucly A, Weatherald J, et al. Drugs targeting novel pathways in pulmonary arterial hypertension. Eur Respir J 2025; 66: 2401830
83. Ghofrani HA, Gomberg-Maitland M, Zhao L, et al. Mechanisms and treatment of pulmonary arterial hypertension. Nat Rev Cardiol. 2025;22:105-120
84. Stump B, Waxman AB. Pulmonary Arterial Hypertension and TGF-β Superfamily Signaling: Focus on Sotatercept. BioDrugs. 2024;38(6):743-753
85. Humbert M, McLaughlin V, Gibbs JSR, et al; PULSAR Trial Investigators. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2021; 384:1204-1215
86. Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023;388(16):1478-1490
87. McLaughlin VV, Hoeper MM, Badesch DB, et al; HYPERION Trial Investigators. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. N Engl J Med;393(16):1599
88. Humbert M, McLaughlin VV, Badesch DB, et al; ZENITH Trial Investigators. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. N Engl J Med; 392(20):1987-2000
89. Abdulelah M, Ezenna C, Jenil-Franco A, et al. Clinical outcomes and safety of sotatercept in pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials. Vascul Pharmacol 2025; 160: 107520.
90. Shalabi L, Tabassum S, Al Zoubi BM, et al. Efficacy and safety of sotatercept in pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Naunyn–Schmiedebergs Arch Pharmacol 2025; in press [https://doi.org/10.1007/s00210-025-04424-0].
91. Preston IR, Badesch D, Ghofrani HA, et al. A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA. Eur Respir J. 2025; 66(1):2401435
92. Hoeper MM. Sotatercept in pulmonary arterial hypertension: revolution, risk and the road ahead. Eur Respir J 2025; 66:2501633
93. KEROS Therapeutics. Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial. Date last updated: 15 January 2025. https://ir.kerostx.com/news-releases/news-release-details/keros-therapeutics-announces-additional-update-phase-2-tropos/
94. Spiekerkoetter E, Sung YK, Sudheendra D, et al. Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension. Eur Respir J 2017; 50: 1602449
95. Martin de Miguel I, Cruz-Utrilla A, Oliver E, et al. Novel Molecular Mechanisms Involved in the Medical Treatment of Pulmonary Arterial Hypertension. Int J Mol Sci. 2023;24(4):4147
96. Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013; 127: 1128–1138.
97. Rothman AMK, Villar S, Middleton J, et al. Positioning Imatinib for pulmonary arterial hypertension: a dose finding phase 2 study. Am J Respir Crit Care Med 2025; 211: 1018–1027.
98. Gillies H, Chakinala MM, Dake BT, et al. IMPAHCT: a randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension. Pulm Circ 2024; 14: e12352.
99. van Campen JSJA, de Boer K, van de Veerdonk MC, et al. Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study. Eur Respir J 2016; 48: 787–796.
100. Zhang H, Wei Y, Zhang C, et al. pulmonary artery denervation for pulmonary arterial hypertension: a sham-controlled randomized PADN-CFDA trial. JACC Cardiovasc Interv 2022; 15: 2412–2423
101. Rabinovitch M, Guignabert C, Humbert M, et al. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res 2014; 115: 165–175
102. Ventetuolo CE, Baird GL, Barr RG, et al. Higher estradiol and lower dehydroepiandrosterone-sulfate levels are associated with pulmonary arterial hypertension in men. Am J Respir Crit Care Med 2016; 193: 1168–1175
103. Kawut SM, Archer-Chicko CL, DeMichele A, et al. Anastrozole in pulmonary arterial hypertension. A randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2017; 195: 360–368.
104. Kawut SM, Feng R, Ellenberg SS, et al. Pulmonary hypertension and anastrozole (PHANTOM): a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2024; 210: 1143–1151.
105. Lu M, Chen L-Y, Gairhe S, et al. Mineralocorticoid receptor antagonist treatment of established pulmonary arterial hypertension improves interventricular dependence in the SU5416-hypoxia rat model. Am J Physiol Lung Cell Mol Physiol 2022; 322: L315–L332
106. Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, et al. Five-year outcomes of patients enrolled in the REVEAL Registry. Chest 2015;148:1043–1054
107. Rosenkranz S, Howard LS, Gomberg-Maitland M, et al. Systemic consequences of pulmonary hypertension and right-sided heart failure. Circulation 2020; 141(8): 678–693
108. Sahay S, Chakinala MM, Kim NH, at al. Contemporary Treatment of Pulmonary Arterial Hypertension: A U.S. Perspective. Am J Respir Crit Care Med. 2024; 210(5):581-592
109. Madonna R, Biondi F. Sotatercept: New drug on the horizon of pulmonary hypertension. Vascul Pharmacol. 2024;157:107442
110. Estrada RA, Sahay S, Tonelli AR. Treatment of pulmonary hypertension after seven world symposia. Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251342898
111. Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014; 129: 57–65
112. Wang P, Hu L, Yin Y, et al. Can anticoagulants improve the survival rate for patients with idiopathic pulmonary arterial hypertension? A systematic review and meta-analysis. Thromb Res 2020; 196: 251–256.
113. Howard LSGE, He J, Watson GMJ, et al. Supplementation with iron in pulmonary arterial hypertension. Two randomized crossover trials. Ann Am Thorac Soc 2021;18:981–988
114. Muñoz L, Coronel ML, Perna ER, et al. Déficit de hierro: una comorbilidad emergente en hipertensión arterial pulmonar. Rev Fed Arg Cardiol. 2024; 53(1): 9-13
115. Olsson K and Channick R. Pregnancy in pulmonary arterial Hypertension. Eur Respir Rev 2016; 25: 431–437.
116. Hemnes AR, Kiely DG, Cockrill BA, et al. Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. Pulm Circ 2015; 5: 435–465.
117. Preston IR, Howard LS, Langleben D, et al., Management of pulmonary hypertension in special conditions. Eur Respir J. 2024;64(4):2401180
118. Morris NR, Kermeen FD, Jones AW, et al. Exercise-based rehabilitation programmes for pulmonary hypertension. Cochrane Database Syst Rev 2023; 3(3): CD011285
119. García-Zamora S, Pulido L , Sosa-Liprandi M, et al. Consensus Document on the Role of Adult Vaccination in the Prevention of Cardiovascular Events. Joint statement by the Argentine Federation of Cardiology (FAC), Argentine Society of Cardiology (SAC), and the Argentine Council of Cardiology Residents (CONAREC). Rev Fed Arg Cardiol. 2025; 54 (Suplemento 7): 3-23
120. Kovacs G, Bartolome S, Denton CP, et al. Definition, classification and diagnosis of pulmonary hypertension. Eur Respir J. 2024; 64:2401324
121. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809–818.
122. Sitbon O, Delcroix M, Bergot E, et al.EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. Am Heart J 2014;167:210–217.
123. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425–434
124. Bourge RC, Waxman AB, Gomberg-Maitland M, et al. Treprostinil administered to treat pulmonary arterial hypertension using a fully implantable programmable intravascular delivery system: results of the DelIVery for PAH trial. Chest 2016;150:27–34.
125. Richter MJ, Harutyunova S, Bollmann T, et al. Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. J Heart Lung Transplant 2018;37:1235–1244
126. Blette BS, Moutchia J, Al-Naamani N, et al. Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials. Lancet Respir Med 2023; 11: 873–882
127. Badagliacca R, D’Alto M, Ghio S, et al. Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension. Am J Respir Crit Care Med 2021; 203: 484–492
128. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55: 1915–1922
129. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322–329
130. Sandoval J, Gaspar J, Peña H, et al. Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. Eur Respir J. 2011;38(6):1343-8.
131. Savale L, Benazzo A, Corris P, et al. Transplantation, bridging, and support technologies in pulmonary hypertension. Eur Respir J. 2024;64(4):2401193
132. Leard L, Holm A, Valapour M, et al. Consensus document for the selection of lung transplant candidates: an update from the international Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2021;40:1349-79.
133. Cantres-Fonseca O, Kennedy JLW. Where's the Easy Button? The Many Barriers to Care for Patients With Pulmonary Arterial Hypertension. J Am Heart Assoc. 2022 Nov 15;11(22): e027967. doi: 10.1161/JAHA.122.027967. Epub 2022 Nov 12. PMID: 36370008; PMCID: PMC9750086
134. Van Alsten SC, Harris JK. Cost-Related Nonadherence and Mortality in Patients With Chronic Disease: A Multiyear Investigation, National Health Interview Survey, 2000-2014. Prev Chronic Dis. 2020 Dec 3;17: E151. doi: 10.5888/pcd17.200244. PMID: 33274701; PMCID: PMC7735485
135. Kjellström B, Sandqvist A, Hjalmarsson C, et al. Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. ERJ Open Res. 2020 Dec 7;6(4):00299-2020. doi: 10.1183/23120541.00299-2020. PMID: 33313301; PMCID: PMC7720683
136. Bluro I, Coronel ML; Atamañuk A, et al. Adherencia y acceso a la medicación en pacientes con Hipertension Arterial Pulmonar en centros de referencia en Argentina. Trabajo N° 0166, presentado en el 49° Congreso Argentino de Cardiología de la Sociedada Argentina de Cardiología, octubre 2023
137. Orozco-Levi M, Souza R, Bluro IM, et al. Pathway to care, treatment and disease burden of pulmonary arterial hypertension: a real-world survey of physicians and patients in Latin America. BMJ Open. 2024;14(12): e087263
138. Prisco SZ, Kantorovich A, Liu Y, et al. PVRI Innovative Drug Development Initiative Access to Care Workstream. Global Resource Disparities Between Pulmonary Hypertension Centers: Results From the International Survey by the PVRI IDDI Access to Care Workstream. Pulm Circ. 2026; 16(1):e70229
139. Newman J, Ghani H, Munagala S, et al. The Pulmonary Hypertension Global Patient Survey: understanding the experiences and perspectives of patients. ERJ Open Res. 2025; 11(6):00297-2025
140. Ghio S, Badagliacca R, D'Alto M, et al. Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up. Eur Heart J. 2026 Epub ahead of print. PMID: 41649944.
